Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN

Tudor Investment Corp ET AL bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 30,015 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,434,000. Tudor Investment Corp ET AL owned 0.05% of Supernus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its position in shares of Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the period. Arizona State Retirement System lifted its position in Supernus Pharmaceuticals by 1.7% during the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after purchasing an additional 277 shares during the period. Hantz Financial Services Inc. grew its stake in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares in the last quarter. Amalgamated Bank increased its holdings in Supernus Pharmaceuticals by 2.0% in the 3rd quarter. Amalgamated Bank now owns 16,030 shares of the specialty pharmaceutical company’s stock valued at $766,000 after buying an additional 313 shares during the period. Finally, Covestor Ltd increased its holdings in Supernus Pharmaceuticals by 29.6% in the 3rd quarter. Covestor Ltd now owns 2,309 shares of the specialty pharmaceutical company’s stock valued at $110,000 after buying an additional 527 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SUPN. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Finally, Stifel Nicolaus raised their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of “Hold” and an average price target of $62.17.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the sale, the chief executive officer owned 958,100 shares in the company, valued at $48,259,497. The trade was a 3.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Georges Gemayel sold 8,787 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $53.00, for a total value of $465,711.00. Following the completion of the transaction, the director directly owned 27,277 shares of the company’s stock, valued at approximately $1,445,681. The trade was a 24.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,881 shares of company stock worth $6,139,356 over the last 90 days. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $49.52 on Monday. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -72.82, a PEG ratio of 1.54 and a beta of 0.70. The firm has a 50 day simple moving average of $50.99 and a 200 day simple moving average of $49.39. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.